Summary

The global market for Antibody-oligonucleotide Conjugates (AOCs) was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ 525 million by 2031 with a CAGR of 147.2% during the forecast period 2025-2031.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
This report aims to provide a comprehensive presentation of the global market for Antibody-oligonucleotide Conjugates (AOCs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antibody-oligonucleotide Conjugates (AOCs) by region & country, by Type, and by Application.
The Antibody-oligonucleotide Conjugates (AOCs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-oligonucleotide Conjugates (AOCs).
Market Segmentation
By Company
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio
Segment by Type
Site-specific Coupling
Random Coupling
Segment by Application
Rare and Genetic Diseases
Cancer Treatment
Central Nervous System Disorders
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Antibody-oligonucleotide Conjugates (AOCs) Product Introduction
1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Forecast (2020-2031)
1.3 Antibody-oligonucleotide Conjugates (AOCs) Market Trends & Drivers
1.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
1.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers & Opportunity
1.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
1.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Players Revenue Ranking (2024)
2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Company (2020-2025)
2.3 Key Companies Antibody-oligonucleotide Conjugates (AOCs) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antibody-oligonucleotide Conjugates (AOCs) Product Offered
2.5 Key Companies Time to Begin Mass Production of Antibody-oligonucleotide Conjugates (AOCs)
2.6 Antibody-oligonucleotide Conjugates (AOCs) Market Competitive Analysis
2.6.1 Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-oligonucleotide Conjugates (AOCs) as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Site-specific Coupling
3.1.2 Random Coupling
3.2 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type
3.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value, by Type (2020-2031)
3.2.3 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rare and Genetic Diseases
4.1.2 Cancer Treatment
4.1.3 Central Nervous System Disorders
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application
4.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value, by Application (2020-2031)
4.2.3 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region
5.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region (2020-2025)
5.1.3 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region (2026-2031)
5.1.4 Global Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
5.2.2 North America Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
5.3.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
5.4.2 Asia Pacific Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
5.5.2 South America Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
5.6.2 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antibody-oligonucleotide Conjugates (AOCs) Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.3 United States
6.3.1 United States Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.3.2 United States Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.4.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.5.2 China Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.5.3 China Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.6.2 Japan Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.7.2 South Korea Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.8.2 Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Antibody-oligonucleotide Conjugates (AOCs) Sales Value, 2020-2031
6.9.2 India Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Type (%), 2024 VS 2031
6.9.3 India Antibody-oligonucleotide Conjugates (AOCs) Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Avidity Biosciences
7.1.1 Avidity Biosciences Profile
7.1.2 Avidity Biosciences Main Business
7.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.1.4 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.1.5 Avidity Biosciences Recent Developments
7.2 Dyne Therapeutics
7.2.1 Dyne Therapeutics Profile
7.2.2 Dyne Therapeutics Main Business
7.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.2.4 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.2.5 Dyne Therapeutics Recent Developments
7.3 Tallac Therapeutics
7.3.1 Tallac Therapeutics Profile
7.3.2 Tallac Therapeutics Main Business
7.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.3.4 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.3.5 Tallac Therapeutics Recent Developments
7.4 Denali Therapeutics
7.4.1 Denali Therapeutics Profile
7.4.2 Denali Therapeutics Main Business
7.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.4.4 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.4.5 Denali Therapeutics Recent Developments
7.5 Gennao Bio
7.5.1 Gennao Bio Profile
7.5.2 Gennao Bio Main Business
7.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.5.4 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.5.5 Gennao Bio Recent Developments
7.6 ChainGen Bio
7.6.1 ChainGen Bio Profile
7.6.2 ChainGen Bio Main Business
7.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Products, Services and Solutions
7.6.4 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Revenue (US$ Million) & (2020-2025)
7.6.5 ChainGen Bio Recent Developments
8 Industry Chain Analysis
8.1 Antibody-oligonucleotide Conjugates (AOCs) Industrial Chain
8.2 Antibody-oligonucleotide Conjugates (AOCs) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antibody-oligonucleotide Conjugates (AOCs) Sales Model
8.5.2 Sales Channel
8.5.3 Antibody-oligonucleotide Conjugates (AOCs) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer